A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Akihiro TsuboiNaoya HashimotoFumihiro FujikiSoyoko MorimotoNaoki KagawaHiroko NakajimaNaoki HosenSumiyuki NishidaJun NakataSatoshi MoritaJunichi SakamotoYusuke OjiYoshihiro OkaHaruo SugiyamaPublished in: Cancer immunology, immunotherapy : CII (2018)
The safety of a cocktail vaccine of WT1 HLA class I and II peptides for malignant gliomas was verified. This vaccine is, therefore, considered promising for patients with recurrent malignant glioma.
Keyphrases